Literature DB >> 20689131

Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation.

Jing Liu1, Robert E Brown.   

Abstract

The mammalian target of rapamycin (mTOR) signaling pathway was studied using immunohistochemical stains on paraffin-embedded tumor tissue from two patients with anaplastic thyroid carcinoma (ATC) and on paraffin-embedded normal thyroid tissue from 23 control patients. Immunoreactivities of p-mTOR, p-Akt, p-p70S6K, and PLD1 were observed in both of the ATCs, with nuclear translocation of p-mTOR, p-Akt, and p-p70S6K. Increased expression of Ki-67, Skp2, and cyclin D1, decreased expression of p27(kip1), and increased mitotic index (MI) were noted in the ATCs in comparison with those of normal thyroid tissue. The results provide evidence of (a) constitutive activation of the mTOR pathway, (b) mTORC2 activation, suggested by the nuclear translocation of p-mTOR, and (c) enhanced cell cycle progression in ATCs. These preliminary findings warrant future studies in a large series of patients with ATC to evaluate a possible molecular basis for treating chemoradioresistant ATC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689131

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  7 in total

1.  Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin.

Authors:  Jing Liu; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2011-10-30

Review 2.  PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.

Authors:  Zahra Nozhat; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

3.  Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.

Authors:  Samira M Sadowski; Myriem Boufraqech; Lisa Zhang; Amit Mehta; Payal Kapur; Yaqin Zhang; Zhuyin Li; Min Shen; Electron Kebebew
Journal:  Oncotarget       Date:  2015-07-20

4.  Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis.

Authors:  Robert E Brown; Robert L Hunter; Shen-An Hwang
Journal:  Front Immunol       Date:  2017-02-02       Impact factor: 7.561

5.  Identification and characterization of two novel oncogenic mTOR mutations.

Authors:  Avaniyapuram Kannan Murugan; Rengyun Liu; Mingzhao Xing
Journal:  Oncogene       Date:  2019-03-27       Impact factor: 9.867

6.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

Review 7.  The PI3K/Akt Pathway in Tumors of Endocrine Tissues.

Authors:  Helen Louise Robbins; Angela Hague
Journal:  Front Endocrinol (Lausanne)       Date:  2016-01-11       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.